Natco Pharma Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Natco Pharma Share Price

860.50-4.50 (-0.53%)

Live
As On: 10 Jun, 2026, 11:38 AM IST
As On: 10 Jun, 2026, 11:39 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	866.70
High	876.80
Low	860.10
Prev Close	865.00
Volume	2,26,010
VWAP(₹)	866.98

Key Metrics

PE Ratio(x)	10.91
EPS - TTM(₹)	79.20
MCap(₹ Cr.)	15,473.30
MCap Rank	36
PB Ratio(x)	1.68
Div Yield(%)	0.58
Face Value(₹)	2.00
52W High(₹)	1,226.80
52W Low(₹)	789.00
MCap/Sales	4.28
Beta(1 Month)	0.45
BV/Share(₹)	514.83

Natco Pharma share price insights

Rank 430 - ET 5002025 ranking

Topline Contraction
Sales de-grew by 8.53%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Candle Formations Yesterday
Black Spinning Top was formed for Natco Pharma
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 16.85% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Natco Pharma Share Price Update
Natco Pharma Ltd. share price moved down by -0.53% from its previous close of Rs 865.00. Natco Pharma Ltd. stock last traded price is 860.50
Share Price Value
Today/Current/Last 860.50860.50
Previous Day 865.00865.55

Found Insights useful?

Natco Pharma Share Price Returns

1 Day	-0.53%
1 Month	-26.75%
3 Months	-17.2%
1 Year	-2.4%
3 Years	37.94%
5 Years	-21.91%

Natco Pharma Share Recommendations

Mean recosCurrent

HOLD

9 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	2	2	2	2
Buy	1	1	1	1
Hold	3	4	4	4
Sell	2	1	1	1
Strong Sell	1	1	2	2
# Analysts	9	9	10	10

Recent Recos

Target₹1145
OrganizationICICI Securities
ADD

Target₹1116
OrganizationGeojit Financial Services
BUY

Target₹875
OrganizationICICI Securities
ADD

View all Stock Recommendations

News & Analysis

Natco Pharma shares crash 15% after weak Q4 results; net profit tanks 34% YoY
News
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcements
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcements

View all Natco Pharma Share News & Announcements

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	816.90	705.40	1,463.00	1,390.60	1,287.30
Total Income Growth (%)	15.81	-51.78	5.21	8.02	97.71
Total Expenses	661.90	534.80	836.20	815.50	771.20
Total Expenses Growth (%)	23.77	-36.04	2.54	5.74	59.67
EBIT	155.00	170.60	626.80	575.10	516.10
EBIT Growth (%)	-9.14	-72.78	8.99	11.43	207.02
Profit after Tax (PAT)	267.90	151.50	518.40	480.70	406.60
PAT Growth (%)	76.83	-70.78	7.84	18.22	205.71
EBIT Margin (%)	18.97	24.18	42.84	41.36	40.09
Net Profit Margin (%)	32.79	21.48	35.43	34.57	31.59
Basic EPS (₹)	14.96	8.46	28.94	26.84	22.70

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	681.70	584.10	1,357.60	1,252.30	1,219.50
Total Income Growth (%)	16.71	-56.98	8.41	2.69	111.87
Total Expenses	562.00	450.60	759.90	706.80	689.90
Total Expenses Growth (%)	24.72	-40.70	7.51	2.45	63.52
EBIT	119.70	133.50	597.70	545.50	529.60
EBIT Growth (%)	-10.34	-77.66	9.57	3.00	244.57
Profit after Tax (PAT)	209.60	106.90	500.90	464.10	428.10
PAT Growth (%)	96.07	-78.66	7.93	8.41	242.75
EBIT Margin (%)	17.56	22.86	44.03	43.56	43.43
Net Profit Margin (%)	30.75	18.30	36.90	37.06	35.10
Basic EPS (₹)	11.70	5.97	27.97	25.91	23.90

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	4,375.90	4,784.00	4,126.90	2,811.70	2,043.80
Total Revenue Growth (%)	-8.53	15.92	46.78	37.57	-5.19
Total Expenses	2,885.10	2,492.60	2,453.40	1,949.80	1,841.60
Total Expenses Growth (%)	15.75	1.60	25.83	5.88	16.85
Profit after Tax (PAT)	1,418.50	1,885.40	1,388.30	715.30	170.00
PAT Growth (%)	-24.76	35.81	94.09	320.76	-61.44
Operating Profit Margin (%)	37.45	52.27	42.33	32.37	11.30
Net Profit Margin (%)	34.78	42.56	34.71	26.42	8.74
Basic EPS (₹)	79.20	105.26	77.34	39.18	9.32

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	3,875.70	4,415.80	3,673.60	2,436.50	1,862.40
Total Revenue Growth (%)	-12.23	20.20	50.77	30.83	6.14
Total Expenses	2,511.60	2,189.80	2,118.30	1,665.80	1,706.50
Total Expenses Growth (%)	14.70	3.38	27.16	-2.38	25.26
Profit after Tax (PAT)	1,281.50	1,850.40	1,306.60	637.10	139.10
PAT Growth (%)	-30.74	41.62	105.09	358.02	-55.06
Operating Profit Margin (%)	38.84	54.84	43.98	33.14	9.57
Net Profit Margin (%)	35.65	45.19	36.61	27.09	7.86
Basic EPS (₹)	71.55	103.31	72.79	34.90	7.63

All figures in Rs Cr, unless mentioned otherwise

Insights

Topline Contraction
Sales de-grew by 8.53%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 16.85% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	11,073.70	8,630.80	6,906.30	5,657.40	5,109.10
Total Assets Growth (%)	28.30	24.97	22.08	10.73	6.62
Total Liabilities	1,852.60	1,018.50	1,053.20	783.60	845.50
Total Liabilities Growth (%)	81.89	-3.29	34.41	-7.32	26.48
Total Equity	9,221.10	7,612.30	5,853.10	4,873.80	4,263.60
Total Equity Growth (%)	21.13	30.06	20.09	14.31	3.40
Current Ratio (x)	3.01	5.59	4.14	4.39	3.52
Total Debt to Equity (x)	0.08	0.04	0.06	0.03	0.09
Contingent Liabilities	0.00	50.70	58.80	22.10	22.40

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	10,287.40	8,269.90	6,554.00	5,387.90	4,978.00
Total Assets Growth (%)	24.40	26.18	21.64	8.23	4.74
Total Liabilities	1,734.80	936.00	961.70	685.90	786.10
Total Liabilities Growth (%)	85.34	-2.67	40.21	-12.75	18.85
Total Equity	8,552.60	7,333.90	5,592.30	4,702.00	4,191.90
Total Equity Growth (%)	16.62	31.14	18.93	12.17	2.46
Current Ratio (x)	2.76	5.42	3.85	4.38	3.34
Total Debt to Equity (x)	0.08	0.04	0.06	0.03	0.09
Contingent Liabilities	0.00	50.70	58.80	55.00	52.30

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	1,768.30	1,696.80	1,211.60	849.10	46.50
Net Cash used in Investing Activities	-2,142.90	-1,414.50	-1,032.70	-477.10	-5.30
Net Cash flow from Financing Activities	297.50	-210.70	-246.90	-363.00	34.80
Net Cash Flow	78.90	49.60	-61.50	20.80	85.30
Closing Cash & Cash Equivalent	198.90	120.00	70.40	131.90	111.10
Closing Cash & Cash Equivalent Growth (%)	65.75	70.45	-46.63	18.72	330.62
Total Debt/ CFO (x)	0.40	0.16	0.30	0.19	8.69

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	1,776.40	1,662.00	1,196.40	784.40	57.70
Net Cash used in Investing Activities	-2,078.20	-1,443.90	-960.50	-436.60	-92.50
Net Cash flow from Financing Activities	302.10	-212.40	-237.30	-346.80	35.60
Net Cash Flow	0.30	5.70	-1.40	1.00	0.80
Closing Cash & Cash Equivalent	11.50	11.20	5.50	6.90	5.90
Closing Cash & Cash Equivalent Growth (%)	2.68	103.64	-20.29	16.95	15.69
Total Debt/ CFO (x)	0.40	0.16	0.30	0.20	6.74

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 2142.9 cr for investing activities which is an YoY increase of 51.5%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	15.38	24.78	23.71	14.67	3.98
Return on Capital Employed (%)	16.26	30.11	28.52	17.61	4.99
Return on Assets (%)	12.80	21.84	20.10	12.64	3.32
Interest Coverage Ratio (x)	47.25	106.72	97.89	71.74	20.48
Asset Turnover Ratio (x)	0.41	0.57	0.64	0.50	0.36
Price to Earnings (x)	12.32	7.58	12.27	14.39	81.30
Price to Book (x)	1.89	1.88	2.91	2.11	3.24
EV/EBITDA (x)	9.58	4.85	8.75	9.52	38.67
EBITDA Margin (%)	42.52	57.57	47.00	38.42	18.63

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	14.98	25.23	23.36	13.54	3.31
Return on Capital Employed (%)	16.01	30.32	27.69	16.17	3.91
Return on Assets (%)	12.45	22.37	19.93	11.82	2.79
Interest Coverage Ratio (x)	49.10	125.80	120.12	108.16	23.13
Asset Turnover Ratio (x)	0.39	0.55	0.60	0.45	0.36
Price to Earnings (x)	13.62	7.72	13.04	16.16	100.00
Price to Book (x)	2.04	1.95	3.05	2.19	3.30
EV/EBITDA (x)	10.70	5.15	9.49	10.79	45.87
EBITDA Margin (%)	44.12	60.21	48.80	39.56	17.40

Found Financials useful?

Share Price Forecast

Exclusively for ETPrime

REVENUE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
EARNINGS
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP
PRICE
Invest in the Best
Check two-year estimates on Price, Revenue & Earnings
READ FOR FREE ON APP

Technicals

Buy/Sell Signals
MACD Crossover
Bearish signal on weekly chart
Appeared on: 5 Jun 2026
Region: Positive
Last Signal 6 Feb 2026 (Loss -0.55%)
Average price decline of -8.83% within 7 weeks of Bearish signal in last 10 years
Price Analysis
42%
Positive Movement
since 1st Jan 2005
on basis
58%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 876.80 Pivot
866.80
S1 855.00
R2 888.60 S2 845.00
R3 910.40 S3 823.20
Average True Range
5 Days 14 Days 28 Days
43.95 46.29 43.52

Found Technicals useful?

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Natco Pharma	10.91	1.68	15.38	16.26	12.80	15.72	37.45	33.63	79.20	3.01	0.08	0.40
Sai Life Science Ltd.	74.53	10.47	14.04	18.38	9.62	21.41	23.41	15.91	16.63	1.69	0.04	0.19
Neuland Labs	60.32	11.71	19.41	23.10	12.42	19.36	25.35	17.99	283.71	2.09	0.10	0.57
Granules India	32.25	3.77	11.70	16.15	7.70	5.91	16.94	11.08	24.47	1.80	0.26	1.69
Caplin Point	28.13	4.97	17.87	21.95	15.85	14.62	36.74	29.70	84.36	6.70	0.00	0.00
Add More

Annual Ratios (%)

Choose from Peers

Aarti Inds
Jubilant Life
Alembic Pharma
Concord Biotech Ltd.
Glenmark Life

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Found Peer Comparison useful?

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 8,85,15,126 49.42 % -0.05
Pledge 0 0.00 % 0.00
FII 3,11,15,988 17.37 % 2.21
DII 97,01,512 5.42 % 0.04
MF 30,73,831 1.72 % 0.11
Others 4,97,77,244 27.78 % -2.19
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 49.42 49.48 49.48 49.56
Pledge 0.00 0.00 0.00 0.00
FII 17.37 15.16 14.09 15.52
DII 5.42 5.38 5.87 5.64
Mutual Funds 1.72 1.60 2.20 2.11
Others 27.78 29.98 30.56 29.28

Mutual Funds Ownership

MF Ownership as on 30 April 2026

Tata Value Direct-G
Equity: Value Oriented
3
- 90.40
  Amount Invested (in Cr.)
- 1.05%
  % of AUM
- 0.00
  % Change (MoM basis)
Sundaram Small Cap Direct-G
Equity: Small Cap
4
- 62.81
  Amount Invested (in Cr.)
- 1.76301%
  % of AUM
- -5.02
  % Change (MoM basis)
Tata Small Cap Direct-G
Equity: Small Cap
2
- 60.16
  Amount Invested (in Cr.)
- 0.53%
  % of AUM
- 0.00
  % Change (MoM basis)

View all Mutual Fund Schemes

Natco Pharma Top Searches

Corporate Actions

Recent
Board Meeting
Audited Results
May 18, 2026
Board Meeting
Scheme of Arrangement
Mar 18, 2026
General Meeting
-
Feb 20, 2026

Announced on	Meeting on
May 18, 2026	May 29, 2026
Audited Results
Mar 18, 2026	Mar 24, 2026
Scheme of Arrangement
Jan 28, 2026	Feb 12, 2026
Quarterly Results & Interim Dividend
Nov 07, 2025	Nov 14, 2025
Quarterly Results & Interim Dividend
Aug 04, 2025	Aug 12, 2025
Quarterly Results & Interim Dividend

Dividends
Announced on Ex-Date Dividend%
Feb 12, 2026 Feb 18, 2026 75%
Nov 14, 2025 Nov 20, 2025 75%
Aug 12, 2025 Aug 19, 2025 100%
Feb 12, 2025 Feb 18, 2025 75%
Nov 12, 2024 Nov 27, 2024 75%
Bonus
No Data Available
Splits
Announced on Ex-Date
Aug 12, 2015 Nov 26, 2015
Split: Old FV10.0| New FV:2.0
Rights
No Data Available

AGM/EGM Meetings

Announced on	Meeting on
Feb 20, 2026	Mar 26, 2026
-
Sep 01, 2025	Sep 25, 2025
-
Aug 12, 2024	-
Book closure from Sep 26, 2024 to Sep 30, 2024
Aug 12, 2024	-
Book closure from Sep 26, 2024 to Sep 30, 2024
Aug 12, 2024	-
Book closure from Sep 26, 2024 to Sep 30, 2024

About Natco Pharma

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 15,493.00 Crore) operating in Pharmaceuticals sector.

Natco Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Agrochemicals, Export Incentives, Other Operating Revenue, Scrap for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 816.90 Crore, up 15.81 % from last quarter Total Income of Rs 705.40 Crore and down 36.54 % from last year same quarter Total Income of Rs 1,287.30 Crore. Company has reported net profit after tax of Rs 233.30 Crore in latest quarter.

The company’s top management includes Mr.V C Nannapaneni, Mr.Rajeev Nannapaneni, Mr.P S R K Prasad, Mr.A D M Chavali, Mr.D Vijaya Bhaskar, Dr.Kantipudi Suma, Mr.Lakshminarayana Bolisetty, Mr.Nitin Jain, Dr.D Linga Rao, Mr.S V V N Appa Rao, Mr.Venkat Ramesh Ch. Company has B S R & Associates LLP as its auditors. As on 31-03-2026, the company has a total of 17.91 Crore shares outstanding.

Natco Pharma Share Price Today is Rs. 860.50. On previous day, the Natco Pharma Share Price (NSE) closed at Rs. 868.3, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 49.42% of the stake in Natco Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Natco Pharma stocks was 17.37% as compared to 15.16% in Dec 2025 with increase of 2.21%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 5.42% as compared to 5.38% in Dec 2025 with increase of 0.04%. Out of the total DII holdings in Natco Pharma shares 1.72% was held by mutual funds. The rest including public held is 27.79%. Natco Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Natco Pharma Dividend: Ever since 1981, Natco Pharma dividends has been paid out around 42 times. As on 10 Jun, 2026, 11:38 AM IST, The overall dividend yield for Natco Pharma stands at 0.58%. The last dividend paid was on February 18, 2026 (Rs. 1.5). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 79.2.

Natco Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 816.9 Cr. of sales and 15.81% of quarterly net profit, there have been multiple ups and downs in the Natco Pharma stock prices in the past few weeks. For example, Natco Pharma stock price on 2nd of June 2026 was around Rs. 939.3. Natco Pharma share price now stands at an average of Rs. 860.50. Judging by last week's performance, stock is in down trend.

Natco Pharma has a median target price of Rs. 989.2 in 12 months by 10 analysts. They have provided a high estimate of Rs. 1220.0 and low estimate of Rs. 712.0 for Natco Pharma share.

Historical Prices and Performance:
Natco Pharma, incorporated in 1981 is a Mid Cap company (with a market cap of Rs. 15493.0) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Natco Pharma stock was 15.38%, 24.78%, 23.71%, 14.67% and 3.98% respectively.
The Natco Pharma share gave a 3 year return of 38.67% as compared to Nifty 50 which gave a return of 25.2%.
Natco Pharma announced 75.0% final dividend on February 18, 2026.

Key Metrics:
PE Ratio of Natco Pharma is 10.96
Prices/Sales Ratio of Natco Pharma is 4.28
Price/Book Ratio of Natco Pharma is 1.69

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Natco Pharma, major competitors and peers include Sai Life Science Ltd., Neuland Labs, Granules India and Caplin Point. As of Dec 2025, the dividend yield of Natco Pharma stands at 0.58% while Sai Life Science Ltd., Neuland Labs, Granules India and Caplin Point stand at 0.0%, 0.2%, 0.23% and 0.18% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 10.96 and 1.69 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 9, Three months ago this number stood at 10. Out of total, 2 analyst have a'Strong Buy' reco, 1 analyst have a'Buy' reco, 3 analyst have a'Hold' reco, 2 analyst have a'Sell' reco.

Mean recommendations by 9 analyst stand at'Buy'.

Leadership of Natco Pharma :
A Lakshminarayana is Sr. Vice President - HR & OD
Amresh Kumar Trivedi is General Manager
M Pulla Reddy is Exe. Vice President - R&D
Rajesh Chebiyam is Exe. Vice President - Crop Health Sciences
Ramesh Dandala is Exe Vice President - Tech. Transfer, IPRs & Regula
Pratima Jain is Vice President
Ramakrishna Sridhar Reddy is Senior Vice President
Sunil Kotaru is Senior Vice President
N Sadasiva Rao is Exe. Vice President - Corp Affairs, Legal & Secret
Barur Praveen Kumar is Vice President
Venkat Rao Tummala is Vice President - Production
Srinivas Ch is Sr. Vice President - Demand & Supply Planning
Sandeep Kumar is Vice President - QA
S V V N Appa Rao is Chief Financial Officer
Venkat Ramesh Ch is Co. Secretary & Compl. Officer
Kurra Venkata Sreenivasa Babu is Vice President - Operations
Rampalli Sriram is Vice President
Gopalakrishnan Vaidyanathan is Sr. Vice President - Analytical R&D
Suryanarayana Reddy Malti is Senior Vice President
Imtiyaz Basade is Senior Vice President - R&D
Yarramshetty Krishna Rao is Senior Vice President - Operations
V C Nannapaneni is Chairman & Managing Director
Rajeev Nannapaneni is Vice Chairman & CEO
P S R K Prasad is Director & Exe. VP (Corp. Engg. Services)
D Linga Rao is Director & President (Tech. Affairs)
D Vijaya Bhaskar is Independent Director
A D M Chavali is Independent Director
Kantipudi Suma is Independent Director
Nitin Jain is Independent Director
Lakshminarayana Bolisetty is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

Nifty Smallcap 100, Nifty 500, BSE 500, BSE 250 SmallCap Index, BSE SmallCap

Address

NATCO House, Road # 2,Banjara Hills,Hyderabad, Telangana - 500034

Contact

investors@natcopharma.co.in

http://www.natcopharma.co.in

Executive Leadership

VC

V C Nannapaneni

Chairman & Managing Director

RN

Rajeev Nannapaneni

Vice Chairman & CEO

PS

P S R K Prasad

Director & Exe. VP (Corp. Engg. Services)

AD

A D M Chavali

Independent Director

Show More

Auditors

B S R & Associates LLP

FAQs about Natco Pharma share

1. What is Natco Pharma share price and what are the returns for Natco Pharma share?
Natco Pharma share price is Rs 860.50 as on 10 Jun, 2026, 11:38 AM IST. Natco Pharma share price is down by 0.53% based on previous share price of Rs 868.3. Natco Pharma share price trend:
- Last 12 Months: Natco Pharma share price moved down 2.40%
- Last 3 Years: Natco Pharma Share price moved up by 37.94%
2. What are the returns for Natco Pharma share?
Return Performance of Natco Pharma Shares:
- 1 Week: Natco Pharma share price moved down by 7.92%
3. What has been highest price of Natco Pharma share in last 52 weeks?
Natco Pharma share price saw a 52 week high of Rs 1,226.80 and 52 week low of Rs 789.00.
4. What is the PE & PB ratio of Natco Pharma?
The PE ratio of Natco Pharma stands at 10.92, while the PB ratio is 1.68.
5. What is the market cap of Natco Pharma?
Natco Pharma share has a market capitalization of Rs 15,473.30 Cr. Within Pharmaceuticals sector, it's market cap rank is 36.

Top Gainers

As on 11:34 AM | 10 Jun 2026

1,229.30

80.21 (6.98%)

1,795.90

109.21 (6.48%)

2,395.10

139.91 (6.21%)

Concord Biotech Ltd.

1,342.70

70.50 (5.55%)

168.83

8.50 (5.30%)

Top Losers

As on 11:35 AM | 10 Jun 2026

169.11

-8.90 (-5.00%)

Manappuram Finance

294.15

-13.11 (-4.27%)

1,384.30

-57.91 (-4.02%)

103.66

-3.97 (-3.68%)

231.24

-8.57 (-3.58%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.